Virology Commons^™

Molecular Basis For Drug Resistance In Hiv-1 Protease, Akbar Ali, Rajintha M. Bandaranayake, Yufeng Cai, Nancy M. King, Madhavi Kolli, Seema Mittal, Jennifer E. Foulkes-Murzycki, Madhavi N. L. Nalam, Ellen A. Nalivaika, Aysegul Ozen, Moses Prabu-Jeyabalan, Kelly Thayer, Celia A. Schiffer

Celia A. Schiffer

HIV-1 protease is one of the major antiviral targets in the treatment of patients infected with HIV-1. The nine FDA approved HIV-1 protease inhibitors were developed with extensive use of structure-based drug design, thus the atomic details of how the inhibitors bind are well characterized. From this structural understanding the molecular basis for drug resistance in HIV-1 protease can be elucidated. Selected mutations in response to therapy and diversity between clades in HIV-1 protease have altered the shape of the active site, potentially altered the dynamics and even altered the sequence of the cleavage sites in the Gag polyprotein. All …

The Role Of Human Ubc9 During The Human Immunodeficiency Virus Replication Cycle, Christopher R. Bohl

School of Biological Sciences: Dissertations, Theses, and Student Research

Human immunodeficiency virus type 1 (HIV-1) is a retrovirus and the causative agent of the acquired immune deficiency syndrome (AIDS) pandemic. The retrovirus replication cycle is divided into early infectious events, which involve the infection and integration of the viral DNA into target cell chromosomes; and late events, which involve the expression of viral genes and assembly of infectious virions. To complete the replication cycle, HIV-1 utilizes various cellular pathways.

We identified the Ubc9 E2 SUMO conjugating enzyme as a HIV-1 Gag interaction partner. When this interaction was disrupted in HIV-1 producer cells by Ubc9 siRNA, the virus that was …